ISLH is committed to ensuring an up to date inventory of guidelines that support the Hematology Laboratory community. You may view our inventory of guidelines by selecting a category/topic below. Please note that the search/sort options will only include guidelines for the currently selected category/topic.
Please note: The “Other” tab contains guidelines/best practice papers that may include both management and laboratory recommendations
Guideline Title | Organization | Year | Action |
---|---|---|---|
Recommendations for Setting a Criterion and Assessing Commutability of Sample Materials Used in External Quality Assessment/Proficiency Testing Schemes |
N/A |
2023 |
|
ISO 15189:2022 Medical Laboratories – Requirements for quality and competence |
ISO |
2022 |
|
International normalized ratio and activated partial thromboplastin time testing |
2022 |
||
International Council for Standardization in Haematology (ICSH) recommendations for processing of blood samples for coagulation testing |
ICSH |
2021 |
|
Recommendations for estimating measurement uncertainty in medical laboratories (ISO 15189 and ISO 20914) |
SIPMeL |
2021 |
|
Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies |
ISTH/SSC |
2021 |
|
Optimal Testing: AACC's Guide to Lab Test Utilization |
AACC |
2020 |
|
Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis |
BSH |
2020 |
|
Strategies for eliciting and synthesizing evidence for guidelines in rare diseases |
BMC |
2019 |
|
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum |
Anticoagulation Forum |
2019 |
|
Croatian Society of Medical Biochemistry and Laboratory Medicine: National recommendations for blood collection, processing, performance and reporting of results for coagulation screening assays prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen and D-dimer. |
Croatian Society of Medical Biochemistry and Laboratory Medicine |
2019 |
|
Joint EFLM-COLABIOCLI Recommendation for venous blood sampling |
EFLM-COLABIOCLI |
2018 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Practice guidelines for BRCA1/2 tumour testing in ovarian cancer |
CCMG and Canadian Association of Pathologists |
2022 |
|
Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies |
CAP |
2021 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
The use of DOACs in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia |
ISTH SSC |
2024 |
|
International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests |
ICSH |
2024 |
|
Guideline for laboratory diagnosis and monitoring of von Willebrand disease: A joint guideline from the United Kingdom Haemophilia Centre Doctors' Organisation and the British Society for Haematology |
UK Haemophilia Centre Doctors’ Organisation / BSH |
2024 |
|
Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper |
2024 |
||
Association of laboratory test results with the bleeding history in patients with inherited platelet function disorders (the BAT-LAB substudy): communication from the Platelet Physiology ISTH-SSC |
ISTH SSC |
2023 |
|
International Council for Standardization in Haematology Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls |
ICSH |
2023 |
|
International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors |
ICSH |
2023 |
|
Multi-center evaluation of light transmission platelet aggregation reagents: Communication from the ISTH SSC Subcommittee on Platelet Physiology |
ISTH |
2023 |
|
Consensus Report on Markers to Distinguish Procoagulant Platelets from Apoptotic Platelets: Communication from the SSC of the ISTH |
ISTH SSC |
2023 |
|
Assays to quantify fibrinolysis: strengths and limitations. Communication from the ISTH SSC Subcommittee on Fibrinolysis |
ISTH SSC |
2023 |
|
Anticoagulation in adult patients supported with extracorporeal membrane oxygenation: guidance from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis |
ISTH SSC |
2022 |
|
Factor V Leiden-independent activated protein C resistance: Communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee |
ISTH SSC |
2022 |
|
Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies |
ISTH SSC |
2022 |
|
Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline |
United Kingdom Haemophilia Centre Doctors’ Organisation |
2022 |
|
Heparin Resistance — Clinical Perspectives and Management Strategies |
|
2021 |
|
Recommendations for clinical laboratory testing for protein S deficiency: Communication from the SSC committee plasma coagulation inhibitors of the ISTH |
ISTH SSC |
2021 |
|
2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulant |
ICSH |
2021 |
|
Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis |
ISTH SSC |
2020 |
|
Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis |
ISTH SSC |
2020 |
|
Update of the guidelines for lupus anticoagulant detection and interpretation |
ISTH SSC |
2020 |
|
Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH |
ISTH SSC |
2020 |
|
Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH |
ISTH SSC |
2019 |
|
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants |
ICSH |
2018 |
|
Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH |
ISTH SSC |
2018 |
|
European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative |
NIH |
2017 |
|
Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations |
NIH |
2017 |
|
Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL |
Blood Transfusion |
2017 |
|
Internal quality control practices in coagulation laboratories: recommendations based on a patterns-of-practice survey |
IQMH |
2015 |
|
Diagnosis of inherited platelet function disorders: Guidance from the SSC of the ISTH |
ISTH |
2015 |
|
Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH |
ISTH |
2014 |
|
Validation of hemostasis and coagulation assays: recommendations and guidelines |
Independent authors (STH) |
2014 |
|
The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology |
UKHCDO / BCSH |
2014 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Guideline for the management of conception and pregnancy in thalassaemia syndromes: A British Society for Haematology Guideline |
BSH |
2024 |
|
Guidelines for the Management of α-Thalassaemia (2023) |
Thalassaemia International Federation |
2024 |
|
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission |
Lancet Haematology Commission |
2023 |
|
Evidence to Improve Care: Sickle Cell Disease – Care for People of All Ages |
Health Quality Ontario |
2023 |
|
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
ASH |
2020 |
|
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain |
ASH |
2020 |
|
ICSH recommendations for assessing automated high-performance liquid chromatography and capillary electrophoresis equipment for the quantitation of HbA2 |
ICSH |
2015 |
|
ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders |
ICSH |
2015 |
|
ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes |
ICSH |
2011 |
|
ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes |
ICSH |
2011 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper |
BSH |
2024 |
|
Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper |
BSH and UK Myeloma Society |
2024 |
|
Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper |
BSH |
2024 |
|
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. |
WHO |
2016 |
|
Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology |
CAP |
2016 |
|
ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features |
ICSH |
2015 |
|
ICSH guidelines for the standardization of bone marrow immunohistochemistry |
ICSH |
2015 |
|
ICSH guidelines for the evaluation of blood cell analyzers including those used for differential leucocyte and reticulocyte counting |
ICSH |
2014 |
|
ICSH guidelines for the verification and performance of automated cell counters for body fluids |
ICSH |
2014 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
CConsensus report on flow cytometry for platelet function testing in thrombocytopenic patients: communication from the SSC of the ISTH |
ISTH SSC |
2023 |
|
Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology |
ISTH SSC |
2021 |
|
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders |
ICCS/ESCCA |
2018 |
|
Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group |
PBC |
2016 |
|
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10 |
ESCCA |
2011 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19 |
ISTH |
2024 |
|
A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH |
ISTH SSC |
2022 |
|
Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH |
ISTH SSC |
2022 |
|
Antithrombotic agents in patients with COVID-19 |
CMAJ |
2022 |
|
Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S |
2022 |
||
COVID-Inflicted Coagulopathy: Expert Consensus on Management with Novel Oral Anticoagulants in India |
2021 |
||
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 |
Ontario Science Table |
2022 |
|
Alert to Health Care Professionals about a potential drug-drug interaction between Paxlovid and anticoagulants |
Thrombosis Canada |
2022 |
|
WHO recommends two new drugs to treat COVID-19 |
WHO |
2022 |
|
The COVID-19 Treatment Guidelines Panel's Statement on Anticoagulation in Hospitalized Patients With COVID-19 |
NIH |
2022 |
|
Evidence-Based Recommendations on the Use of Anti-SARS-CoV-2 Monoclonal Antibodies (Casirivimab + Imdevimab, and Sotrovimab) for Adults in Ontario |
Ontario Science Table |
2021 |
|
Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources |
2021 |
||
VITT, COVID-19 and the Expert Haematology Panel: The story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme |
UK Expert Haematology Panel |
2021 |
|
Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19 |
ADD |
2021 |
|
Evidence-Based Use of Therapeutics for Ambulatory Patients with COVID-19 |
Ontario Science Table |
2021 |
|
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 |
Ontario Science Table |
2021 |
|
COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) |
NICE |
2021 |
|
Guidance for clinical case management of thrombosis with thrombocytopenia syndrome(TTS) following vaccination to prevent coronavirus disease (COVID-19) |
WHO |
2021 |
|
COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets |
EMA |
2021 |
|
The ISTH Releases Interim Guidance on Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) |
ISTH |
2021 |
|
Laboratory testing for post ChAdOx1 nCOV-19 vaccination VITT: A challenge. Comment on: Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology |
ISTH SSC |
2021 |
|
Recommendations for the clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) for SARS-CoV-2 infections: Communication from the ISTH SSC Subcommittee on Platelet Immunology |
ISTH SSC |
2021 |
|
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination: Interim Guidance for Healthcare Professionals in the Outpatient Setting |
COVID-19 Advisory for Ontario |
2021 |
|
Recognizing, managing and reporting vaccineinduced immune thrombotic thrombocytopenia |
2021 |
||
Intensive Care guidance for the management of vaccine induced immune-thrombocytopenia and thrombosis (VITT) |
UK Intensive Care Society and NACCS |
2021 |
|
The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing |
Infectious Diseases Society of America |
2021 |
|
ASH Guidelines on Use of Anticoagulation in Patients with COVID-19 |
ASH |
2021 |
|
The ADAMTS13-von Willebrand factor axis in COVID-19 patients |
2021 |
||
A living WHO guideline on drugs to prevent covid-19 |
WHO |
2021 |
|
Thrombosis Canada Statement on Astrazeneca COVID-19 Vaccine and Thrombosis |
Thrombosis Canada |
2021 |
|
ISTH Statement on Astrazeneca COVID-19 Vaccine and Thrombosis |
ISTH |
2021 |
|
THROMBOSIS CANADA UPDATED STATEMENT ON ASTRAZENECA VACCINE AND BLOOD CLOTS - Thrombosis Canada seeks to reassure the public regarding blood clot risk and COVID-19 vaccines |
Thrombosis Canada |
2021 |
|
Remdesivir for severe covid-19: a clinical practice guideline |
BMJ Rapid Recommendation |
2020 |
|
IFCC Information Guide on COVID-19 |
IFCC |
2020 |
|
Thromboembolism and Anticoagulant Therapy During the COVID-19 Pandemic: Interim Clinical Guidance from the Anticoagulant Forum |
Anticoagulant Forum |
2020 |
|
ISTH interim guidance on recognition and management of coagulopathy in COVID |
ISTH |
2020 |
|
ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment |
ISTH |
2020 |
|
ISTH interim guidance to recognition and management of coagulopathy in COVID-19 |
ISTH |
2020 |
|
Laboratory haemostasis monitoring in COVID-19 |
ISTH |
2020 |
|
Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |
Chinese Society on Thrombosis and Hemostasis |
2020 |
|
Practical guidance for the management of adults with Immune Thrombocytopenia during the COVID-19 pandemic |
Reviewed by UK ITP Forum |
2020 |
|
Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19 |
ISTH SSC |
2020 |
|
Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report |
CHEST |
2020 |
|
The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on Fibrinolysis |
ISTH SSC |
2020 |
|
COVID-19 and its implications for thrombosis and anticoagulation |
ASH |
2020 |
|
A Systematic Approach for Managing Venous Thromboembolism in Patients with COVID-19 |
ISTH |
2020 |
|
Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays |
2020 |
||
Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence based guideline |
2020 |
||
Consensus-Based Clinical Recommendations and Research Priorities for Anticoagulant Thromboprophylaxis in Children Hospitalized for COVID-19 Related Illness |
ISTH SSC |
2020 |
|
Management of the thrombotic risk associated with COVID-19: Guidance for the hemostasis laboratory |
2020 |
||
ISTH DIC subcommittee communication on anticoagulation in COVID-19 |
ISTH SSC |
2020 |
|
Quality of early evidence on the pathogenesis, diagnosis, prognosis and treatment of COVID-19 |
2020 |
||
Venous Thromboembolism in COVID-19 |
2020 |
||
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality |
2020 |
||
The hematology laboratory’s response to the COVID-19 pandemic: A scoping review |
2020 |
||
Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis |
2020 |
||
Routine laboratory testing to determine if a patient has COVID-19 |
Cochrane COVID-19 Diagnostic Test Accuracy Group |
2020 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH |
ISTH SSC |
2024 |
|
Management of Bleeding and Thrombotic Complications During Pediatric Extracorporeal Membrane Oxygenation: The Pediatric Extracorporeal Membrane Oxygenation Anticoagulation CollaborativE Consensus Conference |
PEACE |
2024 |
|
Recommendations on Monitoring and Replacement of Antithrombin, Fibrinogen, and Von Willebrand Factor in Pediatric Patients on Extracorporeal Membrane Oxygenation: The Pediatric Extracorporeal Membrane Oxygenation Anticoagulation Collaborative Consensus Conference |
PEACE |
2024 |
|
Prospective, International, Multisite Comparison of Platelet Isolation Techniques for Genome-Wide Transcriptomics: Communication form the SSC of the ISTH |
ISTH SSC |
2024 |
|
Reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH: R1 |
ISTH SSC |
2024 |
|
Acquired von Willebrand syndrome during extracorporeal membrane oxygenation support: a comprehensive review of current evidence: Communication from the ISTH SSC on Perioperative and Critical Care Thrombosis and Hemostasis |
ISTH SSC |
2024 |
|
Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation |
Chinese Society of Cardiology / Chinese Medical Association / Heart Rhythm Committee of Chinese Society of Biomedical Engineering |
2024 |
|
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Hemophilia A and B based on the GRADE methodology |
ISTH |
2024 |
|
Prevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guideline |
BSH |
2024 |
|
Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding |
ESAIC |
2024 |
|
A British Society for Haematology guideline on the assessment and management of bleeding risk prior to invasive procedures |
BSH |
2024 |
|
International Digestive Endoscopy Network consensus on the management of antithrombotic agents in patients undergoing gastrointestinal endoscopy |
The Korean Society of Gastrointestinal Endoscopy Task Force on Clinical Practice Guidelines |
2024 |
|
Standardisation of Definition and Management for Bleeding Disorder of Unknown Cause: Communication from the SSC of the ISTH |
ISTH SSC |
2024 |
|
Prevention and management of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence |
International Union of Angiology |
2024 |
|
UK Transfusion Laboratory Collaborative: Minimum standards for staff qualifications, training, competency and the use of information technology in hospital transfusion laboratories 2023 |
UK Transfusion Laboratory Collaborative |
2024 |
|
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline |
BSH |
2024 |
|
Management of pregnancy and delivery in congenital fibrinogen disorders: Communication from the ISTH SSC Subcommittee on Factor XIII and Fibrinogen |
ISTH SSC |
2024 |
|
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline |
BSH |
2024 |
|
Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy |
ISTH SSC |
2023 |
|
Clinical care of pediatric patients with or at risk of postthrombotic syndrome: guidance from the ISTH SSC Subcommittee on pediatric and neonatal thrombosis and hemostasis |
ISTH SSC |
2023 |
|
Revised transparency rules for the EU Clinical Trials Information System (CTIS) |
EMA |
2023 |
|
Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa |
N/A |
2023 |
|
A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies |
BSH |
2023 |
|
2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria |
ACR / EULAR |
2023 |
|
Defining Heparin Resistance: Communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis |
ISTH 2023 |
2023 |
|
Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland: Guideline from the Working Party Hemostasis of the Swiss Society of Hematology |
Swiss Society of Hematology |
2023 |
|
Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis |
ESC and ISTH |
2023 |
|
Emergency management of patients with Glanzmann thrombasthenia: consensus reccommendations from the French reference center for inherited platelet disorders |
French reference center for inherited platelet disorders |
2023 |
|
Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance |
EHA, ISTH, EAHAD, ESO |
2023 |
|
Position statement from the Indian Society of Gastroenterology, Cardiological Society of India, Indian Academy of Neurology and Vascular Society of India on gastrointestinal bleeding and endoscopic procedures in patients on antiplatelet and/or anticoagulant therapy |
Indian Society of Gastroenterology, Cardiological Society of India, Indian Academy of Neurology and Vascular Society of India |
2023 |
|
American Society of Hematology 2023 Guidelines for Management of Venous Thromboembolism: Thrombophilia Testing |
ASH |
2023 |
|
GRADE guidance 36: updates to GRADE's approach to addressing inconsistency |
GRADE |
2023 |
|
Saudi Critical Care Society clinical practice guidelines on the prevention of venous thromboembolism in adults with trauma: reviewed for evidence-based integrity and endorsed by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine |
Saudi Critical Care Society |
2023 |
|
British Society for Haematology guideline for anticoagulant management of pregnant individuals with mechanical heart valves |
British Society for Haematology |
2023 |
|
Updated guidance for efficacy and safety outcomes for clinical trials in venous thromboembolism in children: Communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis |
ISTH SSC |
2023 |
|
Communication from the Scientific Standardization Committees of the International Society on Thrombosis and Haemostasis on vascular endothelium-related biomarkers in disseminated intravascular coagulation |
ISTH SSC |
2023 |
|
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management |
2023 |
||
Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care - Second update 2022 |
European Society of Anaesthesiology and Intensive Care |
2023 |
|
Recommendation on the Nomenclature for Anticoagulants: Updated Communication from the ISTH SSC Subcommittee on the Control of Anticoagulation |
ISTH SCC |
2023 |
|
Management of rare inherited bleeding disorders: proposals of the French Reference Centre on Haemophilia and rare coagulation disorders |
French Reference Centre on Haemophilia and rare coagulation disorders |
2023 |
|
Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients |
2023 |
||
Recommendations for standardized definitions, clinical assessment, and future research in pediatric clinically unsuspected venous thromboembolism: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis |
ISTH SSC |
2022 |
|
Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis |
ISTH SSC |
2022 |
|
Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH |
ISTH SSC |
2022 |
|
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) |
ESC and endorsed by ESAIC |
2022 |
|
Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH |
ISTH SSC |
2022 |
|
Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline |
CHEST |
2022 |
|
AGA Clinical Practice Update: Coagulation in Cirrhosis |
AGA |
2019 |
|
Perioperative Management of Direct Oral Anticoagulants in Cardiac Surgery: Practice Recommendations Based on Current Evidence |
2022 |
||
Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH |
ISTH SSC |
2018/2019 |
|
Consensus document of the Spanish Society of Digestives Diseases and the Spanish Society of Thrombosis and Haemostasis on massive nonvariceal gastrointestinal bleeding and direct-acting oral anticoagulants |
Spanish Society of Digestives Diseases and Spanish Society of Thrombosis and Haemostasis |
2022 |
|
The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia |
2022 |
||
AANMCO position paper ‘Appropriateness of prescribing direct oral anticoagulants in stroke and systemic thromboembolism prevention in adult patients with non-valvular atrial fibrillation’ |
ANMCO |
2022 |
|
ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes |
ANMCO |
2022 |
|
2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association |
AHA / ASA |
2022 |
|
Recommendations for standardized definitions, clinical assessment, and future research in pediatric clinically unsuspected venous thromboembolism: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis |
ISTH SSC |
2022 |
|
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum |
Anticoagulant Forum |
2022 |
|
Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022 |
|
2022 |
|
Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding |
AICE / SISET |
2022 |
|
Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute Cardio Vascular Care and the Asia-Pacific Heart Rhythm Society |
ESC Working Group on Thrombosis |
2022 |
|
Basic science research opportunities in thrombosis and hemostasis: Communication from the SSC of the ISTH |
ISTH SSC |
2022 |
|
Bleeding disorders in implant dentistry: a narrative review and a treatment guide |
2022 |
||
American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period |
American College of Gastroenterology and Canadian Association of Gastroenterology |
2022 |
|
Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document |
Multidisciplinary Consensus |
2022 |
|
European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopenic purpura published by the International Society on Thrombosis and Haemostasis |
European Renal Best Practice |
2022 |
|
Electronic diaries in the management of haemophilia gene therapy: Perspective of an expert group from the German, Austrian and Swiss Society on Thrombosis and Haemostasis (GTH) |
German, Austrian and Swiss Society on Thrombosis and Haemostasis (GTH) |
2022 |
|
Management of DOAC in patients undergoing planned surgery or invasive procedure: FCSA position paper |
FCSA |
2021 |
|
Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH |
ISTH SSC |
2021 |
|
European principles of care for women and girls with inherited bleeding disorders |
European Association for Haemophilia and Allied Disorders |
2021 |
|
Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update |
2021 |
||
Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology |
ISTH SSC |
2021 |
|
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation |
ISTH SSC |
2021 |
|
2021 Guidelines on the Diagnosis and Management of VWD |
ASH, ISTH, NHF, WFH |
2021 |
|
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation |
European Heart Rhythm Association |
2021 |
|
Comment: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation |
2021 |
||
Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH |
ISTH SSC |
2020 |
|
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia |
BSH |
2020 |
|
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) |
ECS |
2020 |
|
Standardizing Care to Manage Bleeding Disorders in Adolescents with Heavy Menses—A Joint Project from the ISTH Pediatric/Neonatal and Women's Health SSCs |
ISTH SSC |
2020 |
|
WFH Guidelines for the Management of Hemophilia, 3rd edition |
WFH |
2020 |
|
Investigation and management of erythrocytosi |
2020 |
||
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET |
AICE |
2020 |
|
ISTH Guidelines for Treatment of Thrombotic Thrombocytopenic Purpura |
ISTH |
2020 |
|
International Recommendations On The Diagnosis And Treatment Of Acquired Hemophilia A |
2020 |
||
Anticoagulant therapy for splanchnic vein thrombosis |
ISTH SSC |
2020 |
|
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis |
ISTH SSC |
2020 |
|
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia |
2020 |
||
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura |
ISTH |
2020 |
|
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism |
ASH |
2020 |
|
Canadian stroke best practice recommendations: Management of Spontaneous Intracerebral Hemorrhage, 7th Edition Update 2020 |
Canadian Stroke Best Practice Recommendations (CSBPR) |
2020 |
|
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee |
ACC |
2020 |
|
EULAR recommendations for the management of antiphospholipid syndrome in adults |
EULAR |
2019 |
|
Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Edition |
American Society for Apheresis |
2019 |
|
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome |
McMaster RARE-Bestpractices project group |
2018 |
|
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when |
European Myeloma Network |
2018 |
|
Review of the NICE guidelines for multiple myeloma |
NCBI |
2017 |
|
Acquired hemophilia A: Updated review of evidence and treatment guidance. |
HTRS |
2017 |
|
Guideline for the diagnosis and management of the rare coagulation disorders. A United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology |
UKHCDO / BCSH |
2014 |
|
Patient self-testing and self-management oforal anticoagulant with vitamin K antagonists: guidance from the British Committee for Standards in Haematology |
BCSH |
2014 |
|
Diagnosis and management of acquired coagulation inhibitors: a guideline form UKHCDO |
UKHCDO / BCSH |
2013 |
|
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition) |
UKHCDO / BCSH |
2013 |
|
WFH Guidelines for the Management of Hemophilia, 2nd edition |
WFH |
2012 |
Guideline Title | Organization | Year | Action |
---|---|---|---|
Standardization of definition and management for bleeding disorder of unknown cause: communication from the SCC of the ISTH |
ISTH SSC |
2024 |
|
Recommendations for harmonization of the coagulation screening tests laboratory report |
SIBioC and SIPMel |
2023 |
|
Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders |
French Reference Centre on Haemophilia and Rare Coagulation Disorders |
2023 |
|
WFH GUIDELINES for the MANAGEMENT of HEMOPHILIA – 3rd Edition |
WFH |
2020 |
|
A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH |
ISTH SSC |
2021 |
|
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer |
ASH |
2021 |
|
International Council for Standardization in Haematology Recommendations for Hemostasis Critical Values, Tests, and Reporting |
ICSH |
2020 |
|
Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory |
2020 |
||
Guideline Papers |
ICSH |
2021 |
|
Recommendations on the Standardization of Critical Results in Hematology – Adult Population |
ICSH |
2016 |
|
Guideline Papers |
BSH |
2021 |